New cream may soothe painful rashes from cancer drugs

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adult patients eligible for this inclusion in this study have to fulfil all the following criteria: * Indication: lichenoid skin toxicities / rash which has developed under / after anti-PD-1 therapy. * Male and Female patients ≥18 years of age * Patients that are able to speak and read German or English. * The subject was informed and gave his/her consent to the Institutional Review Boards (IRB)/Independent Ethics Committee (IEC) -approved informed consent Exclusion Criteria: Patients fulfilling any of the following criteria are not eligible for the inclusion in this study: * Patient suffering other skin disease resembling lichenoid skin lesions under anti-PD-1 therapy. * Acute psychiatric illness or acute crisis. * Contraindications to ruxolitinib, e.g. known hypersensitivity or allergy * Topical glucocorticosteroids, topical calcineurin inhibitors and UV light therapy are not allowed during the study or for 1 week before the study beginning. Other JAK inhibitors or potent immunosuppressants such as azathioprine or cyclosporine are not allowed during the study or for 8 weeks before the study beginning. * Women who are pregnant or breast feeding \* * Intention to become pregnant during the course of the study * Known or suspected non-compliance, drug or alcohol abuse. * Patients with an active, serious infection, including localized infections. * Inability to follow the procedures of the study due to language problems, psychological disorders, dementia of the participant. * Participation in another study with topical or oral ruxolitinib within the 30 days preceding and during the present study. * Previous enrolment into the current study. * Enrolment of the investigator, his/her family members, employees and other dependent persons. * Participants must avoid pregnancy during the study. A blood pregnancy test is required before start of therapy, with regular urine tests throughout. Lactating individuals are ineligible. Participants must use effective contraceptives, either: * An ovulation-inhibiting method (e.g., pill, injectable, implant, patch, or vaginal ring) or * An intrauterine device (IUD). * Contraception should extend one week post-study. If pregnancy occurs during or within one week after the study, participants should notify the overseeing physician immediately.